Skip to main content
Clinical Trials/NCT05844475
NCT05844475
Active, not recruiting
Not Applicable

Buccal Strip Gingival Graft With a Xenogeneic Collagen Matrix Versus Free Gingival Graft for Keratinized Mucosa Augmentation at Implant Sites: A Randomized, Controlled, Clinical Trial

Harvard Medical School (HMS and HSDM)1 site in 1 country32 target enrollmentApril 13, 2023
ConditionsSurgery

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Surgery
Sponsor
Harvard Medical School (HMS and HSDM)
Enrollment
32
Locations
1
Primary Endpoint
Sites showing KM≥ 2 mm and AM≥ 1 mm
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

The study aims at comparing two different approaches for soft tissue augmentation at implants lacking keratinized and adherent mucosa width: the free gingival graft (FGG) vs the Buccal Strip Graft in combination with a xenogeneic collagen matrix (BSG + CM)

Detailed Description

Conventional free gingival graft (FGG), serving as control group, will be compared to buccal strip gingival graft (BSG) in combination with a collagen matrix (CM), serving as test group, in terms of clinical, volumetric, ultrasonographic, and patient-reported outcomes related to soft tissue augmentation at implant sites lacking keratinized and adherent mucosa.

Registry
clinicaltrials.gov
Start Date
April 13, 2023
End Date
December 21, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Harvard Medical School (HMS and HSDM)
Responsible Party
Principal Investigator
Principal Investigator

Lorenzo Tavelli

Assistant Professor

Harvard Medical School (HMS and HSDM)

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years,
  • Periodontally and systemically healthy,
  • Full-mouth plaque score and full-mouth bleeding ≤ 20% (measured at four sites per tooth),
  • Presence of at least one dental implant with \< 2 mm of KM and lack of firm/adherent mucosa,
  • Presence of at least 4 mm of keratinized gingiva in two or more teeth nonadjacent to the implant to be treated,
  • Implants diagnosed as healthy (Berglundh et al. 2018),
  • The patient must be able to perform good oral hygiene.
  • Exclusion criteria:
  • Contraindications for surgery,
  • Systemic condition (e.g. diabetes mellitus, HIV, cancer, etc) that could compromise wound healing,

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Sites showing KM≥ 2 mm and AM≥ 1 mm

Time Frame: 6 and 12 months

Number of sites showing at least 2 mm of keratinized mucosa width (in millimeters) and at least of 1 mm of attached mucosa (in millimeters) (outcome expressed as a number)

Secondary Outcomes

  • Volumetric change(6 and 12 months)
  • KM width gain(6 and 12 months)
  • Esthetic assessment(Baseline and 12 months)
  • Post-operative morbidity(Daily, for the first 4 weeks after the procedure)
  • Ultrasonographic strain elastography(Baseline, 3 months, 6 months and 12 months)
  • AM gain(6 and 12 months)
  • Ultrasonographic tissue perfusion(Baseline, 1 week, 2 weeks, 1 month, 3 months, 6 months and 12 months)
  • Treatment satisfaction(12 months)
  • Mucosal thickness (MT) gain(6 and 12 months)

Study Sites (1)

Loading locations...

Similar Trials